ResearchMoz

Pharmaceutical Market Research Reports & Industry Analysis

Our coverage in Pharmaceuticals Industry includes large MNC pharmaceutical companies, mid-sized & specialty pharmaceutical companies, off patent or generic drug manufacturers, biotechnology and life sciences companies, contract research companies. We also cover regulatory guidance, contract sales, manufacturing technologies and raw materials in the pharmaceuticals space.

The extensive research & analysis provides us with insight that is a valuable resource for decision-making in this highly vital sector. Our approach and methodology is will enable you a quick and effective understand the key insights of Pharmaceuticals Industry, thus enabling you to respond as market evolves.

Pharmaceutical

Browse reports in Pharmaceutical

Displaying 651 to 680 (of 3140 records)
Pages: « Prev  17 18 19 20 21 22 23 24 25 26   Next »
Remicade (Rheumatoid Arthritis) Forecast and Market Analysis
Nov 2012   |   By - GlobalData
Remicade (Rheumatoid Arthritis) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Remicade (Rheumatoid Arthritis) Forecast and Market Analysis. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizers Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli...
$3495
PharmaPoint: Rheumatoid Arthritis - Germany Drug Forecast and Market Analysis Event-Driven Update
Nov 2012   |   By - GlobalData
PharmaPoint: Rheumatoid Arthritis Germany Drug Forecast and Market Analysis Event-Driven Update Summary GlobalData has released its new Country report, PharmaPoint: Rheumatoid Arthritis Germany Drug Forecast and Market Analysis Event-Driven Update. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizers Xeljanz (tofacitinib) and...
$4995
Simponi (Rheumatoid Arthritis) Forecast and Market Analysis
Nov 2012   |   By - GlobalData
Simponi (Rheumatoid Arthritis) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Simponi (Rheumatoid Arthritis) Forecast and Market Analysis. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizers Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli...
$3495
PharmaPoint: Rheumatoid Arthritis - Spain Drug Forecast and Market Analysis Event-Driven Update
Nov 2012   |   By - GlobalData
PharmaPoint: Rheumatoid Arthritis Spain Drug Forecast and Market Analysis Event-Driven Update Summary GlobalData has released its new Country report, PharmaPoint: Rheumatoid Arthritis Spain Drug Forecast and Market Analysis Event-Driven Update. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizers Xeljanz (tofacitinib) and novel...
$4995
PharmaPoint: Rheumatoid Arthritis - Italy Drug Forecast and Market Analysis Event-Driven Update
Nov 2012   |   By - GlobalData
PharmaPoint: Rheumatoid Arthritis Italy Drug Forecast and Market Analysis Event-Driven Update Summary GlobalData has released its new Country report, PharmaPoint: Rheumatoid Arthritis Italy Drug Forecast and Market Analysis Event-Driven Update. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizers Xeljanz (tofacitinib) and novel...
$4995
PharmaPoint: Rheumatoid Arthritis - Japan Drug Forecast and Market Analysis Event-Driven Update
Nov 2012   |   By - GlobalData
PharmaPoint: Rheumatoid Arthritis Japan Drug Forecast and Market Analysis Event-Driven Update Summary GlobalData has released its new Country report, PharmaPoint: Rheumatoid Arthritis Japan Drug Forecast and Market Analysis Event-Driven Update. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizers Xeljanz (tofacitinib) and novel...
$4995
PharmaPoint: Rheumatoid Arthritis - China Drug Forecast and Market Analysis Event-Driven Update
Nov 2012   |   By - GlobalData
PharmaPoint: Rheumatoid Arthritis China Drug Forecast and Market Analysis Event-Driven Update Summary GlobalData has released its new Country report, PharmaPoint: Rheumatoid Arthritis China Drug Forecast and Market Analysis Event-Driven Update. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizers Xeljanz (tofacitinib) and novel...
$4995
Xeljanz (tofacitinib) (Rheumatoid Arthritis) Forecast and Market Analysis
Nov 2012   |   By - GlobalData
Xeljanz (tofacitinib) (Rheumatoid Arthritis) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Xeljanz (tofacitinib) (Rheumatoid Arthritis) Forecast and Market Analysis. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizers Xeljanz (tofacitinib) and novel oral therapies...
$3495
PharmaPoint: Rheumatoid Arthritis - Australia Drug Forecast and Market Analysis Event-Driven Update
Nov 2012   |   By - GlobalData
PharmaPoint: Rheumatoid Arthritis Australia Drug Forecast and Market Analysis Event-Driven Update Summary GlobalData has released its new Country report, PharmaPoint: Rheumatoid Arthritis Australia Drug Forecast and Market Analysis Event-Driven Update. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizers Xeljanz (tofacitinib)...
$4995
Tabalumab (Rheumatoid Arthritis) Forecast and Market Analysis
Nov 2012   |   By - GlobalData
Tabalumab (Rheumatoid Arthritis) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Tabalumab (Rheumatoid Arthritis) Forecast and Market Analysis. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizers Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as:...
$3495
PharmaPoint: Seasonal Influenza Vaccines United States Drug Forecast and Market Analysis
Nov 2012   |   By - GlobalData
PharmaPoint: Seasonal Influenza Vaccines United States Drug Forecast and Market Analysis Summary GlobalData has released its new Country report, PharmaPoint: Seasonal Influenza Vaccines United States Drug Forecast and Market Analysis. Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and...
$4995
Fostamatinib (Rheumatoid Arthritis) Forecast and Market Analysis
Nov 2012   |   By - GlobalData
Fostamatinib (Rheumatoid Arthritis) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Fostamatinib (Rheumatoid Arthritis) Forecast and Market Analysis. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizers Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as:...
$3495
PharmaPoint: Seasonal Influenza Vaccines United Kingdom Drug Forecast and Market Analysis
Nov 2012   |   By - GlobalData
PharmaPoint: Seasonal Influenza Vaccines United Kingdom Drug Forecast and Market Analysis Summary GlobalData has released its new Country report, PharmaPoint: Seasonal Influenza Vaccines United Kingdom Drug Forecast and Market Analysis. Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever,...
$4995
Secukinumab (Rheumatoid Arthritis) Forecast and Market Analysis
Nov 2012   |   By - GlobalData
Secukinumab (Rheumatoid Arthritis) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Secukinumab (Rheumatoid Arthritis) Forecast and Market Analysis. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizers Xeljanz (tofacitinib) and novel oral therapies awaiting approval such...
$3495
PharmaPoint: Seasonal Influenza Vaccines France Drug Forecast and Market Analysis
Nov 2012   |   By - GlobalData
PharmaPoint: Seasonal Influenza Vaccines France Drug Forecast and Market Analysis Summary GlobalData has released its new Country report, PharmaPoint: Seasonal Influenza Vaccines France Drug Forecast and Market Analysis. Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough....
$4995
Masitinib (Rheumatoid Arthritis) Forecast and Market Analysis
Nov 2012   |   By - GlobalData
Masitinib (Rheumatoid Arthritis) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Masitinib (Rheumatoid Arthritis) Forecast and Market Analysis. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizers Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as:...
$3495
Baricitinib (Rheumatoid Arthritis) Forecast and Market Analysis
Nov 2012   |   By - GlobalData
Baricitinib (Rheumatoid Arthritis) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Baricitinib (Rheumatoid Arthritis) Forecast and Market Analysis. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizers Xeljanz (tofacitinib) and novel oral therapies awaiting approval such...
$3495
PharmaPoint: Seasonal Influenza Vaccines Italy Drug Forecast and Market Analysis
Nov 2012   |   By - GlobalData
PharmaPoint: Seasonal Influenza Vaccines Italy Drug Forecast and Market Analysis Summary GlobalData has released its new Country report, PharmaPoint: Seasonal Influenza Vaccines Italy Drug Forecast and Market Analysis. Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The...
$4995
Sarilumab (Rheumatoid Arthritis) Forecast and Market Analysis
Nov 2012   |   By - GlobalData
Sarilumab (Rheumatoid Arthritis) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Sarilumab (Rheumatoid Arthritis) Forecast and Market Analysis. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizers Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as:...
$3495
PharmaPoint: Seasonal Influenza Vaccines Spain Drug Forecast and Market Analysis
Nov 2012   |   By - GlobalData
PharmaPoint: Seasonal Influenza Vaccines Spain Drug Forecast and Market Analysis Summary GlobalData has released its new Country report, PharmaPoint: Seasonal Influenza Vaccines Spain Drug Forecast and Market Analysis. Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The...
$4995
Sirukumab (Rheumatoid Arthritis) Forecast and Market Analysis
Nov 2012   |   By - GlobalData
Sirukumab (Rheumatoid Arthritis) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Sirukumab (Rheumatoid Arthritis) Forecast and Market Analysis. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizers Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as:...
$3495
PharmaPoint: Seasonal Influenza Vaccines Japan Drug Forecast and Market Analysis
Nov 2012   |   By - GlobalData
PharmaPoint: Seasonal Influenza Vaccines Japan Drug Forecast and Market Analysis Summary GlobalData has released its new Country report, PharmaPoint: Seasonal Influenza Vaccines Japan Drug Forecast and Market Analysis. Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The...
$4995
Fluzone (Seasonal Influenza Vaccines) Forecast and Market Analysis
Nov 2012   |   By - GlobalData
Fluzone (Seasonal Influenza Vaccines) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Fluzone (Seasonal Influenza Vaccines) Forecast and Market Analysis. Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market...
$3495
PharmaPoint: Seasonal Influenza Vaccines India Drug Forecast and Market Analysis
Nov 2012   |   By - GlobalData
PharmaPoint: Seasonal Influenza Vaccines India Drug Forecast and Market Analysis Summary GlobalData has released its new Country report, PharmaPoint: Seasonal Influenza Vaccines India Drug Forecast and Market Analysis. Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The...
$4995
Fluzone IntraDermal (Seasonal Influenza Vaccines) Forecast and Market Analysis
Nov 2012   |   By - GlobalData
Fluzone IntraDermal (Seasonal Influenza Vaccines) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Fluzone IntraDermal (Seasonal Influenza Vaccines) Forecast and Market Analysis. Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold...
$3495
PharmaPoint: Seasonal Influenza Vaccines China Drug Forecast and Market Analysis
Nov 2012   |   By - GlobalData
PharmaPoint: Seasonal Influenza Vaccines China Drug Forecast and Market Analysis Summary GlobalData has released its new Country report, PharmaPoint: Seasonal Influenza Vaccines China Drug Forecast and Market Analysis. Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The...
$4995
Fluzone High-Dose - (Seasonal Influenza Vaccine) Forecast and Market Analysis
Nov 2012   |   By - GlobalData
Fluzone High-Dose (Seasonal Influenza Vaccine) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Fluzone High-Dose (Seasonal Influenza Vaccine) Forecast and Market Analysis. Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and...
$3495
Afluria (Seasonal Influenza Vaccines) Forecast and Market Analysis
Nov 2012   |   By - GlobalData
Afluria (Seasonal Influenza Vaccines) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Afluria (Seasonal Influenza Vaccines) Forecast and Market Analysis. Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market...
$3495
Influvac (Seasonal Influenza Vaccine) Forecast and Market Analysis
Nov 2012   |   By - GlobalData
Influvac (Seasonal Influenza Vaccine) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Influvac (Seasonal Influenza Vaccine) Forecast and Market Analysis. Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market...
$3495
Fluarix (Seasonal Influenza Vaccine) Forecast and Market Analysis
Nov 2012   |   By - GlobalData
Fluarix (Seasonal Influenza Vaccine) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Fluarix (Seasonal Influenza Vaccine) Forecast and Market Analysis. Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is...
$3495
 
Displaying 651 to 680 (of 3140 records)
Pages: « Prev  17 18 19 20 21 22 23 24 25 26   Next »